CSCs Cancer Research Results

CSCs, Cancer Stem Cells: Click to Expand ⟱
Source:
Type:
Cancer Stem Cells

Phytochemicals (natural plant-derived compounds) that may affect CSCs:
Curcumin
— suppresses self-renewal and pathways (Wnt/Notch/Hedgehog).
Resveratrol
— shown to reduce CSC populations and sphere formation in multiple models.
Sulforaphane (from broccoli sprouts)
— reported to inhibit CSC properties and pathways; active in vitro and in vivo.
EGCG (epigallocatechin-3-gallate, green tea)
— reduces CSC markers and sphere formation in several cancer types.
Quercetin
— reported to inhibit CSC proliferation, self-renewal and invasiveness (breast, endometrial, others).
Berberine
— shown to suppress CSC “stemness” and reduce tumorigenic properties in multiple models.
Genistein (soy isoflavone)
— decreases CSC markers, sphere formation and stemness signaling in prostate/breast/other models.
Honokiol (Magnolia bark)
— shown to eliminate or suppress CSC-like populations in oral, colon, glioma models.
Luteolin
— inhibits stemness/EMT and reduces CSC markers and self-renewal in breast, prostate and other models.
Withaferin A (from Withania somnifera / ashwagandha)
— multiple preclinical reports show WA targets CSCs and reduces tumor growth/metastasis in models.

Circadian disruption in cancer and regulation of cancer stem cells by circadian clock genes: An updated review
Potential Role of the Circadian Clock in the Regulation of Cancer Stem Cells and Cancer Therapy
Can we utilise the circadian clock to target cancer stem cells?
Scientific Papers found: Click to Expand⟱
4687- LT,  QC,    Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells
- in-vitro, Pca, DU145
CSCs↓, EMT↓, MMPs↓, TumCMig↓, TumCI↓,
2589- LT,  Chemo,    Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway
- in-vitro, BC, MDA-MB-231
NRF2↓, HO-1↓, ChemoSen↑, CSCs↓, SIRT1↓,
4530- MAG,    Magnolol inhibits cancer stemness and IL-6/Stat3 signaling in oral carcinomas
- in-vitro, Oral, NA
CSCs↓, ChemoSen↑,
8643- MBZ,    Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1 - in-vitro, BC, SUM159
*toxicity↓, TumCP↓, Apoptosis↑, TumCCA↑, TumVol↓, TumMeta↓, ITGB4↓, CSCs↓, Dose↝, TumCMig↓,
2487- MCT,    Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma
- Review, HCC, NA
toxicity↓, toxicity↓, eff↝, angioG↓, CSCs↓, TSP-1↑, Hif1a↓, VEGF↓, eff↑,
8787- MCT,    Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy
- Review, Var, NA
*toxicity↓, angioG↓, Imm↑, DCells↑, T-Cell↑, CSCs?, chemoR↓, QoL↑, RadioS↑, Synergy↑,
8786- MCT,    Metronomic chemotherapy in cancer treatment: new wine in an old bottle
- Review, Var, NA
eff↑, ChemoSideEff↓, angioG↓, *toxicity↓, PFS↑, Hif1a↓, TumCD↑, CSCs↓, EMT↓, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, CD133↓, TumCCA↑, P21↓, DNAdam↑, Imm↑, Synergy↑, Synergy↑,
8784- MCT,    Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
- Review, Var, NA
Dose↝, TumCG↓, angioG↓, TSP-1↑, CD133↓, CSCs↓,
5800- MET,    Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
- Review, Var, NA
ChemoSen↑, RadioS↑, Imm↑, *AntiDiabetic↑, *AMPK↑, TumCP↓, hepatoP↑, ATP↓, AMP↑, glucoNG↓, ROS↑, compI↓, DNAdam↑, CSCs↓, NP/CIPN↓, chemoP↑, toxicity↓, Trx↓, Synergy↑, cycD1/CCND1↓, CDK4↓, CDK6↓, cycE/CCNE↓, CDK2↓,
3477- MF,    Electromagnetic fields regulate calcium-mediated cell fate of stem cells: osteogenesis, chondrogenesis and apoptosis
- Review, Var, NA
*Ca+2↑, *VEGF↑, *angioG↑, Ca+2↑, ROS↑, Necroptosis↑, TumCCA↑, Apoptosis↑, *ATP↑, *FAK↑, *Wnt↑, *β-catenin/ZEB1↑, *ROS↑, p38↑, MAPK↑, β-catenin/ZEB1↓, CSCs↓, TumCP↓, ROS↑, RadioS↑, Ca+2↑, eff↓, NO↑,
3500- MF,    Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress
- in-vitro, Ovarian, SKOV3
ROS↑, CSCs↓, CD44↓, SOX2↓, cMyc↓, TumMeta↓, TumCI↓, TumCMig↓, CD133↓, Nanog↓,
8675- MLT,    Melatonin combined with antineoplastic drugs or natural products for cancer treatment: An update
- Review, Var, NA
ChemoSen↑, TumCP↓, TumCMig↓, CSCs↓, MDR1↓, chemoP?, IL1β↓, IL6↓, IL8↓, TNF-α↓, COX2/PTGS2↓, iNOS↓, Bcl-2↓, Mcl-1↓, IAP1↓, survivin↓, PCNA↓, Ki-67↓, CC(CDKs/cyclins)↓, TumCMig↓, TumCI↓, Fibronectin↓, Vim↓, N-cadherin↓, MMP2↓, MMP9↓, Synergy↑, Synergy↑, OCT4↓, Nanog↓, ERCC1↓, P-gp/ABCB1↓, EMT↓, Synergy↑, ChemoSen↑,
8780- MSM,    Methylsulfonylmethane Induces Cell Cycle Arrest and Apoptosis, and Suppresses the Stemness Potential of HT-29 Cells
- in-vitro, CRC, HT-29
Apoptosis↑, TumCCA↑, CSCs↓, Dose↝, cl‑PARP↑, cl‑Casp9↑, MMP↓, SOX2↓, OCT4↓, Nanog↓,
5253- NCL,    Niclosamide: Beyond an antihelminthic drug
- Review, Var, NA
TumCP↓, Apoptosis↑, EMT↓, β-catenin/ZEB1↓, TumCG↓, toxicity↓, Wnt↓, LRP6↓, Synergy↑, DR5↑, mTORC1↓, pH↓, CSCs↓, IL6↓, JAK1↓, STAT3↓, ChemoSen↑, TumCG↓, tumCV↓, NOTCH↓, NF-kB↓, EGFR↓, ROS↑, RadioS↑, cFos↓, cJun↓, E2Fs↓, cMyc↓, Half-Life↓, BioAv↝,
4630- OLE,    Targeting resistant breast cancer stem cells in a three-dimensional culture model with oleuropein encapsulated in methacrylated alginate microparticles
- in-vitro, BC, NA
Bcl-2↓, BAX↑, Casp3↑, Casp9↑, Vim↓, Slug↓, E-cadherin↑, CSCs↓, P21↑, survivin↝, OCT4↑, Nanog↑, SOX4↑,
1662- PBG,    The immunomodulatory and anticancer properties of propolis
- Review, Var, NA
IL6↓, IL12↓, IL10↑, CSCs↓, PAK1↓, VEGF↓, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, ChemoSen↑, RadioS↑,
4949- PEITC,    Phenethyl Isothiocyanate Exposure Promotes Oxidative Stress and Suppresses Sp1 Transcription Factor in Cancer Stem Cells
- in-vitro, Cerv, HeLa
ROS↑, selectivity↑, CSCs↓, Sp1/3/4↓, P-gp/ABCB1↓, ALDH↓, GSH↓, TumCP↓, Apoptosis↑,
4952- PEITC,    Cancer-preventive effect of phenethyl isothiocyanate through tumor microenvironment regulation in a colorectal cancer stem cell xenograft model
- in-vitro, CRC, HCT116
CSCs↓,
4956- PEITC,    Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells
- vitro+vivo, Lung, A549
GSH↓, ROS↑, mtDam↑, mitResp↓, MMP↓, CSCs↓, OCT4↓, ABC↓, SOX2↓, CD133↓, CD44↓, ALDH↓, Nanog↓, TumCG↓,
4957- PEITC,    Phenethyl Isothiocyanate (PEITC) from Cruciferous Vegetables Targets Human Cancer Stem-Like Cells
- vitro+vivo, Cerv, HeLa
CSCs↓, ALDH↓, CD44↓, CD24↓, cl‑PARP↑, DR4↑, DR5↑,
4958- PEITC,    Cancer-preventive effect of phenethyl isothiocyanate through tumor microenvironment regulation in a colorectal cancer stem cell xenograft model
- vitro+vivo, CRC, NA
CSCs↓, TumCG↓, Inflam↓,
4959- PEITC,    Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment
- in-vitro, Ovarian, NA
CSCs↓, ALDH↓, CSCsMark↓, Synergy↑,
4960- PEITC,    Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells
- in-vivo, Cerv, HeLa
CD44↓, CD24↓, CSCs↓, cl‑PARP↑, DR4↑, DR5↑, TumCP↓,
4961- PEITC,    Phenethyl isothiocyanate suppresses cancer stem cell properties in vitro and in a xenograft model
- vitro+vivo, CRC, HCT116
CSCs↓, TumCG↓, CSCsMark↓,
4962- PEITC,  Ba,  PSO,    Targeting Breast Cancer Stem Cells
- Review, BC, NA
CSCs↓,
4936- PEITC,    PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth
- in-vivo, BC, MDA-MB-231
TumCG↓, CD34↓, CD11b↓, CSCs↓, ALC∅, CD4+↓, NF-kB↓, STAT3↓, Hif1a↓,
5213- PI,    Induction of apoptosis by piperine in human cervical adenocarcinoma via ROS mediated mitochondrial pathway and caspase-3 activation
- in-vitro, Cerv, HeLa
Apoptosis↑, TumCG↓, ROS↑, MMP↓, DNAdam↑, Casp3↑, TumCCA↑, *Inflam↓, *antiOx↓, *hepatoP↑, ChemoSen↑, CSCs↓,
5163- PLB,    Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells
- in-vitro, SCC, SCC25
TumCP↓, NRF2↓, TumCCA↑, EMT↓, CSCs↓, eff↓, ROS↑, CycB/CCNB1↓, CDK1↓, CDK2↓, CDC25↓, Vim↓, OCT4↓, SOX2↓, Nanog↓, BMI1↓, NQO1↓, GSTA1↓, HSP90↓, toxicity↓,
7430- Poly,    Polyphenols as Modulator of Oxidative Stress in Cancer Disease: New Therapeutic Strategies
- Review, Var, NA
*antiOx↑, ROS↑, CSCs↓, NF-kB↓, HDAC⇅, HATs⇅, DNMTs⇅,
4968- PSO,    Psoralidin: emerging biological activities of therapeutic benefits and its potential utility in cervical cancer
- in-vitro, Cerv, NA
*Inflam↓, *antiOx↑, *neuroP↑, *AntiDiabetic↑, *Bacteria↓, AntiTum↑, CSCs↓, ROS↑, TumAuto↑, Apoptosis↑, ChemoSen↑, RadioS↑, BioAv↓, *cardioP↑, *ROS↓, *LDH↓, TumCP↓, TRAIL⇅, TumCMig↓, EMT↓, NF-kB↓, P53↑, Casp3↑, NOTCH↓, CSCs↓, angioG↓, VEGF↓, Ki-67↓, CD31/PECAM-1↓, TRAILR↑, MMP↓, BioAv↓, BioAv↑,
5157- PTL,    An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
- vitro+vivo, AML, NA
CSCs↓, selectivity↑, BioAv↓, BioAv↑, ROS↑, NF-kB↓, P53↑,
5156- PTL,    Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells
- in-vitro, AML, NA
NADPH↑, PPP↑, NRF2↑, ROS↑, CSCs↓, selectivity↑, other↝,
1989- PTL,    Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties
- Review, Var, NA
eff↑, NF-kB↓, STAT↓, ROS↑, Inflam↓, Wnt↓, TCF-4↓, LEF1↓, GSH↓, MMP↓, Casp↑, eff↓, CSCs↓,
1991- PTL,    A novel SLC25A1 inhibitor, parthenolide, suppresses the growth and stemness of liver cancer stem cells with metabolic vulnerability
- in-vitro, Liver, HUH7
TumCCA↑, Apoptosis↑, CSCs↓, ROS↑, OXPHOS↓, MMP↓, SLC25A1↓, IDH2↓,
1236- PTS,    Pterostilbene inhibits the metastasis of TNBC via suppression of β-catenin-mediated epithelial to mesenchymal transition and stemness
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
TumMeta↓, EMT↓, E-cadherin↑, Zeb1↓, Snail↓, β-catenin/ZEB1↓, CD44↓, MMPs↓, CSCs↓,
4701- PTS,  RES,    Targeting cancer stem cells and signaling pathways by resveratrol and pterostilbene
- Review, Var, NA
CSCs↓, E-cadherin↑, NF-kB↓, EMT↓, GRP78/BiP↓, CD133↓, COX2/PTGS2↓, β-catenin/ZEB1↓, NOTCH↓,
4700- PTS,    Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-κB/microRNA 448 circuit
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7
CSCs↓, NF-kB↓, Twist↓, Vim↓, E-cadherin↑,
4698- PTS,    Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF ‐κ B /microRNA 448 circuit
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
CSCs↓, NF-kB↓, Twist↓, Vim↓, E-cadherin↑, miR-448↑,
4696- PTS,    BlueBerry Isolate, Pterostilbene, Functions as a Potential Anticancer Stem Cell Agent in Suppressing Irradiation-Mediated Enrichment of Hepatoma Stem Cells
- in-vitro, HCC, NA
CD133↓, CSCs↓,
4695- PTS,    Pterostilbene in Cancer Therapy: Enhancing Treatment Efficacy and Overcoming Resistance
- Review, Var, NA
CSCs↓, ChemoSen↑, BioAv↑, *toxicity↓,
4694- PTS,    Pterostilbene as a Multifaceted Anticancer Agent: Molecular Mechanisms, Therapeutic Potential and Future Directions
- Review, Var, NA
BioAv↑, AntiCan↑, Casp↑, TumCCA↑, angioG↓, TumMeta↓, MMP9↓, VEGF↓, CSCs↓, CD44↓, cMyc↓, ChemoSen↑, mTOR↓,
4692- PTS,    Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol
- in-vitro, Cerv, HeLa
TumCG↓, TumMeta↓, TumCCA↑, ROS↑, Apoptosis↑, MMP2↓, MMP9↓, CD133↓, OCT4↓, SOX2↓, Nanog↓, STAT3↓, CSCs↓,
4690- PTS,  immuno,    Pterostilbene: Mechanisms of its action as oncostatic agent in cell models and in vivo studies
- Review, Var, NA
eff↑, Half-Life↑, TumCG↓, TumMeta↓, angioG↓, CSCs↓, Apoptosis↑, Synergy↑, CD44↓, CD24↓,
4689- PTS,    Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol
- in-vitro, Cerv, HeLa
eff↑, TumCCA↑, ROS↑, MMP2↓, MMP9↓, CSCs↓, CD133↓, OCT4↓, SOX2↓, Nanog↓, STAT3↓, BioAv↑, TumCI↓, ROS↑, Apoptosis↑,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP/DDIT3↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2/KDR/Flk1↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1/ATG6↑, IL1β↓, CRP↓, IL10↓, COX2/PTGS2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
55- QC,    Quercetin inhibits the growth of human gastric cancer stem cells by inducing mitochondrial-dependent apoptosis through the inhibition of PI3K/Akt signaling
- in-vitro, GC, GCSCs
Bcl-2↓, BAX↑, Cyt‑c↑, MMP↓, PI3K/Akt↓, Casp3↑, Casp9↑, TumCG↓, Apoptosis↑, CSCs↓,
58- QC,  doxoR,    Quercetin induces cell cycle arrest and apoptosis in CD133+ cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin
- in-vitro, CRC, HT-29 - in-vitro, NA, CD133+
Bcl-2↓, TumCCA↑, CD133↓, CSCs↓, ChemoSen↑, CycB/CCNB1↑, cycE/CCNE↓, cycD1/CCND1↓, E2Fs↓,
59- QC,    Quercetin Inhibits Breast Cancer Stem Cells via Downregulation of Aldehyde Dehydrogenase 1A1 (ALDH1A1), Chemokine Receptor Type 4 (CXCR4), Mucin 1 (MUC1), and Epithelial Cell Adhesion Molecule (EpCAM)
- in-vitro, BC, MDA-MB-231
ALDH1A1↓, CXCR4↓, MUC1↓, EpCAM↓, CSCs↓, TumCP↓, TumCI↓, CD44↓, CD24↓, Apoptosis↑, TumCCA↑,
60- QC,  EGCG,  isoFl,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, pCSCs
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, CSCs↓, Apoptosis↑, TumCMig↓, TumCI↓, CD44↓, CD133↓,
61- QC,    Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, ARPE-19
p‑PI3K↓, p‑Akt↓, p‑ERK↓, NF-kB↓, p38↓, ABCG2↓, CD44↓, CD133↓, CSCs↓,

Showing Research Papers: 151 to 200 of 264
Prev Page 4 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 264

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Catalase↓, 1,   Fenton↑, 1,   GPx4↓, 4,   GSH↓, 8,   GSH↑, 3,   GSH/GSSG↓, 1,   GSR↓, 2,   GSR↑, 1,   ox-GSSG↑, 1,   GSTs↑, 1,   H2O2↑, 1,   HO-1↓, 1,   HO-1↑, 9,   Iron↑, 5,   Keap1↑, 1,   lipid-P↓, 1,   lipid-P↑, 4,   MDA↓, 2,   MPO↓, 1,   NQO1↓, 1,   NQO1↑, 4,   NRF2↓, 6,   NRF2↑, 9,   RNS↑, 1,   ROS↓, 6,   ROS↑, 100,   mt-ROS↑, 1,   SOD↓, 3,   SOD↑, 2,   mt-SOD↑, 1,   SOD1↓, 2,   SOD2↑, 1,   Thiols↓, 2,   Trx↓, 1,   TrxR↓, 2,   xCT/SLC7A11↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 3,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

BCR-ABL↓, 1,   CDC2↓, 2,   CDC25↓, 3,   compI↓, 4,   compII↓, 1,   compIV↓, 1,   compV↓, 1,   EGF↓, 1,   ETC↝, 1,   IDH2↓, 1,   mitResp↓, 7,   mitResp↑, 2,   Mortalin↓, 1,   mtDam↑, 8,   OCR↓, 4,   OCR↑, 1,   OXPHOS↓, 6,   OXPHOS↑, 3,   SIRT3↓, 2,   SIRT3↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 2,   ACLY↓, 2,   ALAT↓, 1,   AMP↑, 1,   AMPK↓, 1,   AMPK↑, 10,   p‑AMPK↑, 1,   ATP↓, 18,   ECAR↓, 1,   FAO↓, 1,   FASN↓, 1,   FASN↑, 1,   GAPDH↓, 1,   glucoNG↓, 1,   GlucoseCon↓, 4,   GlutMet↓, 1,   Glycolysis↓, 16,   GSK‐3β↓, 4,   GSK‐3β↑, 2,   GSK‐3β↝, 1,   p‑GSK‐3β↓, 4,   Histones↑, 1,   HK2↓, 3,   HMG-CoA↓, 4,   lactateProd↓, 5,   LDHA↓, 2,   lipoGen↓, 1,   NAD↓, 1,   NADPH↓, 1,   NADPH↑, 3,   PDK1 / PDPK1↓, 3,   PDKs↓, 2,   PFK↓, 2,   PFK1↓, 1,   PKM2↓, 1,   PKM2↑, 1,   PPP↑, 1,   SIRT1↓, 3,   SIRT1↑, 1,   SIRT2↓, 1,   SLC25A1↓, 1,   SREBP1/SREBF1↓, 1,   TCA↓, 2,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

AIF↑, 5,   Apoptosis↓, 2,   Apoptosis↑, 76,   Apoptosis∅, 1,   mt-Apoptosis↑, 2,   BAD↓, 1,   Bak↑, 2,   BAX↑, 27,   Bax:Bcl2↑, 13,   Bcl-2↓, 35,   Bcl-xL↓, 4,   BIM↑, 1,   BNIP3↑, 1,   Casp↓, 1,   Casp↑, 11,   Casp10↑, 1,   Casp12↑, 2,   Casp3↓, 1,   Casp3↑, 37,   cl‑Casp3↑, 6,   Casp7↑, 6,   Casp8↑, 8,   Casp8∅, 1,   Casp9↑, 22,   p‑Casp9↑, 1,   cl‑Casp9↑, 3,   Cyt‑c↑, 20,   Diablo↑, 2,   DR5↑, 10,   Fas↑, 7,   FasL↑, 1,   Ferroptosis↑, 7,   HEY1↓, 2,   IAP1↓, 2,   ICAD↓, 1,   ICD↑, 3,   iNOS↓, 3,   Mcl-1↓, 6,   Mcl-1↑, 1,   MOMP↑, 2,   Necroptosis↑, 1,   necrosis↑, 2,   p38↓, 2,   p38↑, 7,   p‑p38↓, 1,   PUMA↑, 1,   Pyro↑, 1,   survivin↓, 20,   survivin↝, 1,   TNFR 1↑, 1,   TRAIL↑, 1,   TRAIL⇅, 1,   TRAILR↑, 3,   TumCD↑, 14,   XIAP↓, 11,   YAP/TEAD↓, 5,   YAP/TEAD↝, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 44,   Akt↑, 1,   p‑Akt↓, 9,   AKT1↓, 2,   CaMKII ↓, 1,   CK2↓, 3,   cMET↓, 1,   DDIT4↑, 1,   EF-1α↓, 1,   EGFR↓, 14,   ERK↓, 6,   ERK↑, 3,   p‑ERK↓, 4,   FGFR1↓, 1,   HER2/EBBR2↓, 8,   HGF/c-Met↓, 1,   Hippo↓, 1,   IGF-1R↓, 1,   IGFR↓, 1,   IKKα↓, 4,   JAK↓, 2,   JAK1↓, 1,   JAK2↓, 5,   JNK↓, 1,   JNK↑, 8,   p‑JNK↓, 1,   MAPK↓, 10,   MAPK↑, 6,   MARK4↓, 1,   MEK↓, 1,   mTOR↓, 34,   p‑mTOR↓, 2,   p70S6↓, 1,   P70S6K↓, 1,   PDGFR-BB↓, 2,   PDGFRA↓, 2,   PI3K↓, 36,   p‑PI3K↓, 2,   PI3K/Akt↓, 2,   PI3k/Akt/mTOR↓, 1,   PKCδ↓, 2,   PKCδ↑, 1,   PTEN↑, 5,   Raf↓, 2,   c-Raf↓, 1,   RAS↓, 1,   RET↓, 1,   p‑S6K↓, 1,   Sp1/3/4↓, 5,   STAT↓, 3,   STAT3↓, 40,   STAT3↝, 1,   p‑STAT3↓, 4,   STAT5↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF3↑, 1,   ATF4↑, 2,   CBP↓, 1,   cJun↓, 3,   cJun↑, 1,   cMyc↓, 23,   cMyc↑, 1,   DNMT1↓, 5,   DNMT3A↓, 1,   DNMTs⇅, 1,   EZH2↓, 3,   FOXM1↓, 1,   FOXO↑, 2,   FOXO3↑, 4,   FOXO3↝, 1,   FOXO4↓, 1,   FOXO4↑, 1,   GATA3↓, 1,   H3↓, 1,   H3↑, 2,   H3K27ac↓, 1,   H3K9↓, 1,   H4↑, 1,   HATs↓, 2,   HATs↑, 1,   HATs⇅, 1,   HDAC↓, 6,   HDAC⇅, 1,   HDAC1↓, 1,   HDAC3↓, 1,   HOTAIR↓, 1,   miR-10a-5p↝, 1,   miR-133a-3p↑, 1,   miR-141↑, 1,   miR-145↑, 1,   miR-155↝, 1,   miR-200c↑, 2,   miR-21↓, 1,   miR-21↑, 1,   miR-218↑, 1,   miR-27a-3p↓, 1,   miR-34a↓, 1,   miR-34a↑, 5,   miR-34a↝, 1,   miR-375↑, 1,   miR-448↑, 1,   miR-485↑, 1,   Myc↓, 1,   Myc↑, 1,   MYCN↑, 1,   n-MYC↓, 2,   NDRG1↑, 1,   OCT4↓, 37,   OCT4↑, 1,   OLIG2↓, 1,   other↓, 3,   other↑, 1,   other↝, 8,   PCAF↓, 1,   SOX2↓, 25,   SOX4↓, 3,   SOX4↑, 1,   SOX9?, 1,   SOX9↓, 2,   SUV39H↓, 2,   SUZ12↓, 1,   TCF-4↓, 1,   TFE3↑, 2,   tumCV↓, 16,   YMcells↑, 1,   ZBTB10↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   CHOP/DDIT3↑, 12,   cl‑CHOP/DDIT3↑, 1,   eIF2α↓, 1,   ER Stress↑, 18,   ERStress↑, 1,   GRP78/BiP↓, 3,   GRP78/BiP↑, 3,   HSP27↓, 3,   HSP70/HSPA5↓, 4,   HSP90↓, 8,   HSPs↑, 1,   Proteasome?, 1,   Proteasome↓, 2,   UPR↑, 5,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 2,   ATG7↑, 1,   autoF↓, 2,   Beclin-1/ATG6↓, 1,   Beclin-1/ATG6↑, 3,   CTSB↓, 1,   CTSK↓, 1,   CTSL↓, 1,   CTSS↓, 1,   CTSZ↓, 1,   LC3B-II↑, 2,   LC3II↓, 1,   LC3II↑, 5,   LC3s↓, 1,   lysoMP↑, 1,   lysosome↓, 1,   lysosome↝, 1,   MitoP↑, 1,   p62↓, 4,   p62↑, 1,   SESN2↑, 1,   TumAuto↓, 1,   TumAuto↑, 22,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   BRCA1↓, 1,   BRCA1↑, 1,   DFF45↑, 1,   DNAdam↓, 1,   DNAdam↑, 31,   DNArepair↓, 1,   ERCC1↓, 1,   m-FAM72A↓, 1,   hTERT/TERT↓, 1,   MGMT↓, 1,   p16↑, 2,   P53↑, 30,   p‑P53↑, 1,   PARP↓, 1,   PARP↑, 4,   cl‑PARP↑, 15,   cl‑PARP↝, 1,   PCNA↓, 9,   POLD1↓, 1,   RAD51↓, 1,   SIRT6↓, 2,   Telomerase↓, 5,   TOP2↓, 2,   TOP2↑, 1,   TP53↑, 2,   γH2AX↑, 4,  

Cell Cycle & Senescence(tgid=11) ⓘ

AURKB↓, 1,   CC(CDKs/cyclins)↓, 1,   CDK1↓, 9,   CDK1↑, 1,   p‑CDK1↓, 1,   CDK2↓, 8,   CDK2↑, 1,   CDK4↓, 15,   CDK4↑, 1,   CDK6↓, 4,   CDK6↑, 1,   CHK1↓, 2,   CHK1↑, 1,   Chk2↓, 2,   Chk2↑, 1,   Cyc↓, 1,   cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 7,   CycB/CCNB1↑, 2,   cycD1/CCND1↓, 29,   cycD1/CCND1↑, 3,   CycD3↓, 1,   cycE/CCNE↓, 7,   E2Fs↓, 4,   E2Fs↑, 1,   Ki-67↓, 7,   mitA↓, 1,   p19↑, 1,   P21?, 1,   P21↓, 1,   P21↑, 17,   p27/CDKN1B↑, 8,   p‑pRB↓, 1,   RB1↑, 1,   p‑RB1↓, 3,   Securin↓, 1,   TumCCA?, 1,   TumCCA↓, 4,   TumCCA↑, 66,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 18,   ALDH1A1↓, 13,   ALDH1A3↓, 1,   BMI1↓, 4,   CD133↓, 37,   CD133↑, 1,   CD24↓, 12,   CD34↓, 2,   cFos↓, 3,   CLOCK↓, 1,   cMYB↓, 1,   CSCs?, 2,   CSCs↓, 259,   CSCs↑, 4,   CSCs↝, 1,   CSCsMark↓, 4,   Diff↓, 2,   Diff↑, 3,   FGF↓, 1,   Gli↓, 4,   Gli1↓, 12,   Gli1↝, 1,   HH↓, 13,   HH↝, 1,   HMGCR↓, 2,   IGF-1↓, 4,   IGFBP3↑, 1,   Ki-67↓, 7,   LGR5↓, 1,   LRP6↓, 3,   p‑LRP6↓, 1,   mTORC1↓, 3,   p‑mTORC1↓, 1,   Nanog↓, 40,   Nanog↑, 1,   Nestin↓, 5,   NOTCH↓, 13,   NOTCH1↓, 15,   NOTCH2↓, 1,   NOTCH3↓, 4,   p300↓, 2,   PTCH1↓, 5,   PTCH2↓, 1,   Shh↓, 13,   Smo↓, 8,   TumCG↓, 51,   TumCG↑, 1,   TumCP↓, 58,   TumCP↑, 1,   Wnt↓, 43,   Wnt↑, 1,   Wnt/(β-catenin)↓, 3,  

Migration(tgid=13) ⓘ

ACTA2↓, 1,   annexin II↓, 1,   AP-1↓, 3,   Ca+2↓, 1,   Ca+2↑, 11,   Ca+2↝, 1,   cal2↓, 1,   cal2↑, 1,   CCN2/CTGF↓, 2,   CD11b↓, 1,   Chl↓, 1,   Chl↑, 1,   COL1↓, 1,   COL3A1↓, 1,   E-cadherin↓, 3,   E-cadherin↑, 23,   EMT↓, 68,   EpCAM↓, 5,   FAK↓, 6,   Fibronectin↓, 3,   Furin↓, 1,   GLI2↓, 5,   GLI2↝, 1,   ITGB1↓, 1,   ITGB4↓, 1,   LAMs↓, 1,   LEF1↓, 5,   MALAT1↓, 1,   MMP1↓, 1,   MMP2↓, 33,   MMP2↑, 1,   MMP7↓, 2,   MMP9↓, 38,   MMPs↓, 11,   MUC1↓, 1,   MUC1-C↓, 1,   N-cadherin↓, 15,   NCAM↓, 1,   PAK1↓, 3,   PAK1↑, 1,   PDGF↓, 2,   RECK↑, 1,   Rho↓, 1,   ROCK1↓, 1,   Slug↓, 13,   Smad1↓, 1,   SMAD2↓, 3,   SMAD3↓, 3,   Snail↓, 21,   TET1↓, 1,   TET1↑, 1,   TGF-β↓, 10,   TIMP1↓, 1,   TIMP1↑, 2,   TIMP2↓, 1,   TIMP2↑, 2,   TRIB3↑, 2,   TSP-1↑, 5,   TumCI↓, 38,   TumCMig↓, 35,   TumMeta↓, 34,   TumMeta↑, 1,   TumPF↓, 1,   Twist↓, 6,   uPA↓, 8,   uPAR↓, 1,   Vim?, 1,   Vim↓, 26,   Zeb1↓, 8,   α-SMA↓, 1,   β-catenin/ZEB1↓, 49,   β-catenin/ZEB1↑, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 42,   angioG↑, 2,   CCN1/CYR61↓, 1,   CD31/PECAM-1↓, 1,   ECM/TCF↓, 1,   Endoglin↓, 1,   HIF-1↓, 2,   Hif1a↓, 24,   Hypoxia↓, 1,   LymphAG↓, 1,   NO↑, 1,   VCAM-1↓, 1,   VEGF↓, 39,   VEGFR1↓, 1,   VEGFR2/KDR/Flk1↓, 5,  

Barriers & Transport(tgid=15) ⓘ

EPR↑, 1,   GLUT1↓, 1,   GLUT2↓, 1,   MMP↓, 46,   MMP↑, 1,   MPT↑, 5,   ZO-1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ALC∅, 1,   CCR7↓, 1,   CD25+↓, 1,   CD4+↓, 2,   CD44↓, 56,   CD8+↑, 2,   COX2/PTGS2↓, 24,   COX2/PTGS2↑, 1,   CXCL12↓, 2,   CXCR4↓, 9,   DCells↑, 1,   DR4↑, 3,   FoxP3+↓, 1,   HMGB1↓, 3,   ICAM-1↓, 1,   IFN-γ↓, 1,   IL1↓, 1,   IL10↓, 2,   IL10↑, 1,   IL12↓, 3,   IL1β↓, 8,   IL2↓, 1,   IL6↓, 20,   IL8↓, 6,   Imm↑, 11,   Imm↝, 1,   Inflam↓, 14,   M2 MC↓, 2,   MCP1/CCL2↓, 3,   NF-kB?, 1,   NF-kB↓, 62,   NF-kB↑, 1,   p‑NF-kB↓, 1,   NLRP3↓, 1,   p50↓, 1,   p65↓, 1,   PAF↓, 1,   PD-1↓, 1,   PD-L1↓, 1,   PD-L1↑, 1,   PGE2↓, 6,   PSA↓, 1,   RAGE↓, 1,   T-Cell↑, 1,   TCF↓, 3,   TCF↝, 1,   TCF7/TCF1↓, 1,   Th1 response↑, 1,   TLR4↓, 2,   TNF-α↓, 9,  

Cellular Microenvironment(tgid=17) ⓘ

pH↓, 1,   pH↝, 1,   e-pH↑, 1,   i-pH↓, 1,  

Protein Aggregation(tgid=19) ⓘ

XO↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,   ER-α36↓, 2,   ER-α36↝, 1,   FGF21↓, 1,   PPARγ↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABC↓, 2,   ABCG2↓, 4,   BioAv↓, 13,   BioAv↑, 17,   BioAv↝, 5,   BioEnh↑, 1,   chemoR↓, 3,   ChemoSen↑, 81,   ChemoSen⇅, 1,   CompStab↓, 1,   Dose?, 1,   Dose↓, 2,   Dose↑, 3,   Dose⇅, 1,   Dose↝, 20,   Dose∅, 2,   DrugR↓, 1,   eff?, 1,   eff↓, 16,   eff↑, 40,   eff↝, 10,   eff∅, 1,   GSTA1↓, 1,   GSTA1↑, 1,   GSTZ1↓, 1,   GSTZ1↝, 1,   Half-Life↓, 5,   Half-Life↑, 2,   Half-Life↝, 4,   MDR1↓, 7,   P-gp/ABCB1↓, 15,   P450↓, 3,   RadioS↑, 29,   selectivity↑, 36,   selectivity↝, 2,   Synergy↑, 61,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AR↓, 2,   AST↓, 1,   BRCA1↓, 1,   BRCA1↑, 1,   CRP↓, 2,   E6↓, 2,   E7↓, 2,   EGFR↓, 14,   EZH2↓, 3,   Ferritin↓, 3,   FOXM1↓, 1,   HER2/EBBR2↓, 8,   hTERT/TERT↓, 1,   IL6↓, 20,   LDH↓, 4,   LDH↑, 2,   Myc↓, 1,   Myc↑, 1,   PD-L1↓, 1,   PD-L1↑, 1,   PSA↓, 1,   RAGE↓, 1,   SUZ12↓, 1,   TG/TAG↓, 1,   TP53↑, 2,   TRIB3↑, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 17,   antiNeop↑, 4,   AntiTum↓, 1,   AntiTum↑, 7,   cardioP↑, 1,   chemoP?, 1,   chemoP↑, 8,   chemoPv↑, 4,   ChemoSideEff↓, 3,   fatigue↓, 1,   FTO↑, 1,   hepatoP↑, 3,   neuroP↑, 1,   NP/CIPN↓, 1,   NP/CIPN↑, 1,   OS↑, 6,   PFS↑, 1,   Pin1↓, 2,   QoL↑, 3,   radioP↑, 2,   Remission↑, 1,   RenoP↑, 1,   Risk↓, 4,   toxicity↓, 11,   toxicity↑, 2,   toxicity⇅, 1,   toxicity↝, 5,   TumVol↓, 11,   TumW↓, 4,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,   GutMicro↑, 2,   GutMicro↝, 1,   Sepsis↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 2,  
Total Targets: 691

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 17,   Catalase↑, 4,   GPx↑, 4,   GPx1↑, 1,   GPx4↑, 2,   GSH↑, 5,   GSTs↑, 4,   H2O2↑, 1,   HDL↑, 1,   HO-1↓, 1,   HO-1↑, 6,   i-Iron↓, 1,   Keap1↓, 2,   lipid-P↓, 3,   MDA↓, 5,   MPO↓, 1,   NRF2↑, 9,   Prx↑, 1,   ROS↓, 19,   ROS↑, 1,   ROS∅, 1,   selenoP↑, 1,   SOD↑, 7,   SOD1↑, 2,   SOD2↑, 2,   xCT/SLC7A11↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

DRP1/DNM1L↓, 1,   MFN2↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 1,   ALAT↓, 1,   AMPK↓, 1,   AMPK↑, 4,   ATP↓, 1,   ATP↑, 2,   glucose↓, 1,   glucose↝, 1,   GlucoseCon↑, 2,   GSK‐3β↑, 1,   HMG-CoA↓, 1,   NAD↓, 1,   SIRT1↑, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   BAX↓, 1,   Bcl-2↓, 1,   Casp3?, 1,   Casp3↓, 3,   Casp9↓, 2,   Cyt‑c↓, 1,   Fas↓, 1,   Ferroptosis↓, 2,   iNOS↓, 5,   p38↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   Akt↑, 1,   ERK↓, 1,   p‑ERK↑, 1,   HGF/c-Met↑, 1,   JNK↓, 1,   p‑JNK↓, 1,   MAPK↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF2↑, 1,   ATF4↓, 1,   FOXO3↑, 1,   HDAC↓, 1,   HDAC3↓, 1,   other↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   CHOP/DDIT3↑, 1,   GRP78/BiP↑, 1,   GRP94↑, 1,   HSP70/HSPA5↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1,   LC3II↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   P53↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

GADD34↓, 1,   Ki-67↓, 1,   P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

HH↓, 1,   Ki-67↓, 1,   NOTCH↓, 1,   Wnt↓, 1,   Wnt↑, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   FAK↑, 1,   LAMs↑, 1,   MMP3↓, 1,   MMP9↓, 1,   Smad1↑, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 2,   Hif1a↑, 1,   NO↓, 2,   NO↑, 2,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↓, 1,   BBB↑, 1,   GLUT2↑, 2,   GLUT3↑, 1,   GLUT4↑, 2,   H+/K+-ATPase↓, 1,   MMP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 1,   COX2/PTGS2↓, 5,   IFN-γ↓, 1,   IL10↓, 1,   IL17↓, 1,   IL18↓, 1,   IL1β↓, 3,   IL6↓, 6,   IL8↓, 1,   Imm↓, 1,   Imm↑, 1,   Inflam↓, 16,   Inflam↑, 1,   NF-kB↓, 2,   PGE2↓, 2,   PGE2↑, 1,   Th1 response↓, 1,   Th2↑, 2,   TLR4↓, 2,   TNF-α↓, 8,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 2,   BDNF↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ACE/ACE1↓, 1,   ACE2↓, 1,   p‑PPARγ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 7,   BioAv↑, 11,   BioAv↝, 7,   CompStab↑, 1,   Dose↑, 1,   eff↑, 1,   Half-Life↓, 1,   Half-Life↝, 2,   Half-Life∅, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   BMD↑, 1,   CRP↓, 1,   IL6↓, 6,   IRes↝, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 2,   antiAll↑, 2,   AntiArt↑, 1,   AntiCan↑, 2,   AntiDiabetic↑, 5,   cardioP↑, 6,   CardioT↓, 1,   chemoP↑, 1,   chemoPv↑, 2,   cognitive↑, 1,   hepatoP↑, 7,   memory↑, 2,   neuroP↑, 14,   Obesity↓, 2,   Pain↓, 1,   RenoP↑, 2,   Stroke↓, 1,   toxicity↓, 11,   toxicity↝, 3,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 1,   AntiFungal↑, 1,   AntiP↑, 2,   AntiViral↑, 1,   Bacteria↓, 4,   GutMicro↑, 3,  
Total Targets: 171

Scientific Paper Hit Count for: CSCs, Cancer Stem Cells
28 salinomycin
19 Curcumin
15 Resveratrol
15 EGCG (Epigallocatechin Gallate)
14 Sulforaphane (mainly Broccoli)
14 Quercetin
12 Ashwagandha(Withaferin A)
10 Phenethyl isothiocyanate
10 Pterostilbene
6 HydroxyTyrosol
6 Ivermectin
5 Apigenin (mainly Parsley)
5 Disulfiram
5 Honokiol
4 Silver-NanoParticles
4 Artemisinin
4 Berberine
4 Dichloroacetate
4 Emodin
4 Genistein (soy isoflavone)
4 metronomic chemo
4 Parthenolide
3 Isovitexin
3 Radiotherapy/Radiation
3 Bufalin/Huachansu
3 Copper and Cu NanoParticles
3 Eugenol
3 Evodiamine
3 Chemotherapy
3 isoflavones
3 Juglone
2 Astragalus
2 Alpha-Lipoic-Acid
2 Atorvastatin
2 Baicalein
2 Propolis -bee glue
2 chaetocin
2 immunotherapy
2 Fisetin
2 Garcinol
2 Glabrescione B
2 Hyperthermia
2 Isoliquiritigenin
2 Luteolin
2 Magnetic Fields
2 Psoralidin
1 3-bromopyruvate
1 Auranofin
1 Allicin (mainly Garlic)
1 Anethole/trans-Anethole
1 Fennel Oil/Foeniculum vulgare
1 Astaxanthin
1 Berbamine
1 bempedoic acid
1 Betulinic acid
1 temozolomide
1 Brutieridin–Melitidin Mixture
1 Boswellia (frankincense)
1 Caffeic acid
1 NTP, Non-Thermal Plasma,Cold Atmospheric Plasma
1 Carvacrol
1 Cynanbungeigenin C (CBC) and D (CBD)
1 Cannabidiol
1 Celecoxib
1 Chlorogenic acid
1 Cucurbitacin
1 CUSP9
1 Dandelion Root
1 5-fluorouracil
1 Electrical Pulses
1 Gallic acid
1 Ginkgolide B
1 Isobavachalcone
1 iodine
1 isoorientin
1 itraconazole
1 Kaempferol
1 Licorice
1 Lemongrass Extract/Citral
1 Magnolol
1 mebendazole
1 Metformin
1 Melatonin
1 Methylsulfonylmethane
1 Niclosamide (Niclocide)
1 Oleuropein
1 Piperine
1 Plumbagin
1 Polyphenols
1 doxorubicin
1 Rosmarinic acid
1 Silymarin (Milk Thistle) silibinin
1 Shikonin
1 Selenite (Sodium)
1 Aflavin-3,3′-digallate
1 Ursolic acid
1 Vitamin C (Ascorbic Acid)
1 Vitexin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:795  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page